Know Labs, Inc. Reports Third Quarter FY 2024 Results

Rhea-AI Summary

Know Labs, Inc. (NYSE American: KNW) reported Q3 FY 2024 financial results, showing a net loss of $4.10 million, up 13.9% from Q3 FY 2023. Earnings per share improved to a loss of $0.05 from $0.07 last year. R&D expenses decreased by 28.2% to $1.35 million, while SG&A expenses increased to $2.49 million. The company's cash position decreased to $2.13 million from $8.02 million at the end of FY 2023. Know Labs closed a $3.45 million public offering in August 2024, expecting to fund operations until at least December 31, 2024. The company plans to seek additional funding to ensure operations into 2025 and is taking steps to address negative shareholder equity through debt conversion.

Positive

• Earnings per share improved to a loss of $0.05 from $0.07 in the previous year
• R&D expenses decreased by 28.2% to $1.35 million due to completion of development milestones
• Closed a $3.45 million public offering in August 2024, extending operational runway

Negative

• Net loss increased by 13.9% to $4.10 million in Q3 FY 2024
• Cash position decreased to $2.13 million from $8.02 million at the end of FY 2023
• Shareholder equity turned negative at -$4.60 million
• SG&A expenses increased by $1.13 million to $2.49 million
• Audit opinion contains a going concern qualification

Insights

Financial Analyst

Know Labs' Q3 FY2024 results reveal a challenging financial position. The company's net loss increased by 13.9% year-over-year to $4.10 million, despite a 28.2% decrease in R&D expenses. The negative shareholder equity of $4.60 million is concerning, as is the going concern qualification from auditors.

The company's cash position has significantly deteriorated, with cash and equivalents dropping from $8.02 million to $2.13 million over nine months. While the recent $3.45 million public offering provides some relief, the company's high burn rate and need for additional funding raise questions about long-term viability.

Investors should closely monitor Know Labs' ability to secure further funding and its progress in reducing expenses, as these factors will be critical for the company's survival beyond 2024.

Medical Research Analyst

Know Labs' focus on non-invasive medical diagnostic technology positions it in a promising but competitive field. The significant reduction in R&D expenses (28.2% year-over-year) could be viewed positively if it reflects efficient milestone completion. However, it may also indicate a slowdown in innovation, which is important in this rapidly evolving sector.

The company's ability to balance cost-cutting with continued innovation will be critical. While the use of consultants has reduced product development costs, it's essential to ensure this doesn't compromise the quality or pace of research. The upcoming months will be important in determining whether Know Labs can translate its technology into marketable products that can generate revenue and attract further investment.

Market Research Analyst

Know Labs' financial struggles reflect the challenges faced by early-stage medical technology companies. The increase in selling, general and administrative expenses, primarily due to key hires and legal costs, suggests the company is preparing for future growth. However, this comes at a time when cash reserves are dwindling.

The market's reception to the recent $3.45 million public offering will be a key indicator of investor confidence. The company's plan to seek additional funding under the S-3 shelf registration statement will be important for its survival. Investors should watch for any progress in product development or strategic partnerships that could enhance Know Labs' market position and attract further investment.

The negative shareholder equity and going concern qualification may make it challenging to secure favorable terms for future funding rounds, potentially leading to significant dilution for existing shareholders.

SEATTLE--(BUSINESS WIRE)-- Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostic technology, today reported financial results for the third quarter of the fiscal year 2024 ended June 30, 2024.

Financial Highlights:

• In Q3 FY 2024, Know Labs reported a net loss of $4.10 million dollars, compared to a net loss of $3.60 million dollars in Q3 FY 2023, an increase in net loss of 13.9%. This translates to earnings per share of a loss of $0.05, better than the prior year earnings per share loss of $0.07, before preferred stock dividends.
• Recorded a non-cash charge to earnings of $1.58 million dollars principally related to stock-based compensation of $1.0 million dollars, ​​amortization of operating lease right-of-use asset of $276,000, and interest expense for the extension of notes and warrants of $240,000.
• Research and development expense for Q3 FY 2024 was $1.35 million dollars as compared to $1.88 million dollars in Q3 FY 2023, a decrease of 28.2% year over year. The decrease was due primarily to the completion of hardware and software product development milestones and continued use of consultants to reduce the cost of product development.
• Selling, general and administrative expenses for Q3 FY 2024 was $2.49 million dollars, which was higher by $1.13 million dollars than the $1.36 million dollars in the year ago period. The increase was due primarily to salary expenses for several key hires, legal expenses related to financing activities and intellectual property assets, and an increase in stock-based compensation.
• As of June 30, 2024, Know Labs had cash and cash equivalents of $2.13 million dollars, as compared to $8.02 million dollars at the end of September 30, 2023. Net cash used in operations for the first nine months of FY 2024 was $9.57 million dollars compared with $8.98 million dollars in the same nine-month period of FY 2023.
• The Company is undertaking initiatives to significantly reduce fixed expenses and monthly burn rate. Subsequent to the end of Q3 FY 2024, on August 9, 2024, Know Labs closed a firm commitment underwritten public offering of $3.45 million dollars; which with the cash on hand, the Company believes that it has enough available cash and flexibility with its operating expenses to operate until at least December 31, 2024.
• As noted in the Q3 FY 2024 10-Q, the Company plans to seek additional funding under the effective S-3 shelf registration statement to ensure operations well into 2025.
• Shareholder equity for Q3 FY 2024 was a negative $4.60 million dollars versus $3.74 million dollars in FY 2023, ending September 30, 2023. The Company is actively taking steps to address its negative shareholder equity through the conversion of convertible debt to equity.

As previously disclosed in its annual report on Form 10-K for the fiscal year ended September 30, 2023, which was filed with the Securities and Exchange Commission on December 19, 2023, the audit opinion contained a going concern qualification from the Company's independent registered public accounting firm. This announcement is being made solely to comply with the New York Stock Exchange's Company Guide Sections 401(h) and 610(b), which require separate disclosure of receipt of an audit opinion that contains a going concern qualification. This announcement does not represent any change or amendment to the Company's 2023 audited financial statements or to its 2023 annual report on Form 10-K.

Conference Call:

Know Labs will host an audio webcast to discuss its results and provide a business update today, August 14, 2024, at 4:30 pm ET (1:30 pm PT). The live webcast will be available on the Investors page of the Company’s website, https://ir.knowlabs.co/, and a replay will be available for six months.

Participant Dial-In: 877-514-3621 / +1 215-268-9856

Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=bN3zHkNr

A copy of the form 10-Q filed with the SEC can also be downloaded from the Company’s website.

Income Statement:

		Three Months Ended,				Nine Months Ended,
		June 30, 2024		June 30, 2023		June 30, 2024		June 30, 2023
OPERATING EXPENSES-
RESEARCH AND DEVELOPMENT EXPENSES	$	1,348,985	$	1,879,519	$	5,010,618	$	6,186,039
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES		2,486,846		1,359,782		7,025,503		5,507,511
Total operating expenses		3,835,831		3,239,301		12,036,121		11,693,550
OPERATING LOSS		(3,835,831)		(3,239,301)		(12,036,121)		(11,693,550)
OTHER INCOME (EXPENSE), NET
Interest income		30,619		23,511		126,872		114,325
Interest expense		(298,248)		-		(1,038,499)		(389,626)
Other (expense)		-		(384,137)		-		(384,137)
Total other expense, net		(267,629)		(360,626)		(911,627)		(659,438)
LOSS BEFORE INCOME TAXES		(4,103,460)		(3,599,927)		(12,947,748)		(12,352,988)
Income tax expense		-		-		-		-
NET LOSS		(4,103,460)		(3,599,927)		(12,947,748)		(12,352,988)
Deemed dividends on Series C and D  Preferred Stock		(100,045)		(3,337,494)		(262,283)		(3,337,494)
Common stock dividends on Series D Preferred Stock		-		(1,627,230)		-		(1,627,230)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	$	(4,203,505)	$	(8,564,651)	$	(13,210,031)	$	(17,317,712)
Basic and diluted loss per share	$	(0.05)	$	(0.18)	$	(0.16)	$	(0.36)
Weighted average shares of common stock outstanding- basic and diluted		83,038,866		48,928,911		82,314,925		48,604,274

Balance Sheet:

		June 30, 2024		September 30, 2023 (1)
ASSETS		(Unaudited)
CURRENT ASSETS:
Cash and cash equivalents	$	2,129,954	$	8,023,716
Total current assets		2,129,954		8,023,716
PROPERTY AND EQUIPMENT, NET		88,668		81,325
OTHER ASSETS
Other assets		159,244		15,766
Operating lease right-of-use asset		364,342		145,090
TOTAL ASSETS	$	2,742,208	$	8,265,897
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY
CURRENT LIABILITIES:
Accounts payable - trade	$	1,255,888	$	1,292,861
Accrued expenses		116,666		94,062
Accrued expenses - related parties		99,692		218,334
Current portion of convertible notes payable, net		4,539,818		2,761,931
Current portion of operating lease right-of-use liability		105,653		154,797
Total current liabilities		6,117,717		4,521,985
NON-CURRENT LIABILITIES:
Operating lease liability, net of current portion		280,714		-
Non-current portion of convertible notes payable, net		945,258		-
Total liabilities		7,343,689		4,521,985
COMMITMENTS AND CONTINGENCIES (Note 11)
STOCKHOLDERS’ (DEFICIT) EQUITY
Preferred stock - $0.001 par value, 5,000,000 shares authorized, Series C and D shares issued and outstanding as follows:
Series C  Convertible Preferred stock $0.001 par value, 30,000 shares authorized, 17,858 shares issued and outstanding at 6/30/2024 and 9/30/2023, respectively		1,790		1,790
Series D  Convertible Preferred stock $0.001 par value, 20,000 shares authorized, 10,161 shares issued and outstanding at 6/30/2024 and 9/30/2023, respectively		1,015		1,015
Common stock - $0.001 par value, 200,000,000 shares authorized, 86,368,897 and 80,358,463 shares issued and outstanding at 6/30/2024 and 9/30/2023, respectively		86,369		80,358
Additional paid in capital		130,360,164		125,501,537
Accumulated deficit		(135,050,819)		(121,840,788)
Total stockholders' (deficit) equity		(4,601,481)		3,743,912
TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY	$	2,742,208	$	8,265,897

Cash Flow:

		Nine Months Ended,
		June 30, 2024		June 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(12,947,748)	$	(12,352,988)
Adjustments to reconcile net loss to net cash (used in) operating activities
Depreciation and amortization		59,009		259,541
Stock based compensation - stock option grants		2,331,516		2,464,045
Issuance of common stock for services		277,010		-
Loss on disposal of assets		-		384,137
Amortization of operating lease right-of-use asset		162,647		96,161
Amortization of debt issuance costs		375,859		-
Interest expense for extension of notes and warrants		594,761		349,721
Changes in operating assets and liabilities:
Other long-term assets		(143,478)		(1,999)
Operating lease right-of-use liability		(150,329)		(99,803)
Accounts payable - trade and accrued expenses		(133,011)		(74,866)
NET CASH (USED IN) OPERATING ACTIVITIES		(9,573,764)		(8,976,051)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of research and development equipment		(66,352)		(80,798)
NET CASH (USED IN) INVESTING ACTIVITIES:		(66,352)		(80,798)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from debt offering		3,805,699		-
Proceeds from issuance of common stock offering, net		203,105		-
Payments for debt offering		(262,450)		-
Proceeds from issuance of common stock for stock options exercise		-		4,687
Proceeds from issuance of common stock for warrant exercise		-		387,335
NET CASH PROVIDED BY FINANCING ACTIVITIES		3,746,354		392,022
NET (DECREASE) IN CASH AND CASH EQUIVALENTS		(5,893,762)		(8,664,827)
CASH AND CASH EQUIVALENTS, beginning of period		8,023,716		12,593,692
CASH AND CASH EQUIVALENTS, end of period	$	2,129,954	$	3,928,865
Supplemental disclosure of non-cash financing activity:
Deemed dividends on Series C and D Preferred Stock	$	262,283	$	3,337,494
Common stock dividends on Series D Preferred Stock	$	-	$	1,627,230
Warrants issued for debt offering	$	1,536,743	$	-
Common stock issued for debt payment	$	240,000	$	-

About Know Labs, Inc.

Know Labs, Inc. is a public company whose shares trade on the NYSE American Exchange under the stock symbol “KNW.” The Company’s platform technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of the technology will be in a product marketed as a non-invasive glucose monitor. The device will provide the user with accessible and affordable real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration clearance prior to its introduction to the market.

Safe Harbor Statement

This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2023, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240814552248/en/

For Know Labs Media Inquiries Contact:

Matter Health

Abby Mayo

Knowlabs@matternow.com

Ph. (617) 272-0592



Know Labs, Inc. Contact:

Jess English

jess@knowlabs.co

Ph. (206) 629-6414

Source: Know Labs, Inc.

FAQ

What was Know Labs' (KNW) net loss for Q3 FY 2024?

Know Labs reported a net loss of $4.10 million for Q3 FY 2024, an increase of 13.9% compared to the same period last year.

How much cash does Know Labs (KNW) have as of June 30, 2024?

As of June 30, 2024, Know Labs had cash and cash equivalents of $2.13 million.

What was the outcome of Know Labs' (KNW) public offering in August 2024?

Know Labs closed a firm commitment underwritten public offering of $3.45 million on August 9, 2024.

How long does Know Labs (KNW) expect its current cash to last?

Know Labs believes it has enough cash to operate until at least December 31, 2024, and plans to seek additional funding to ensure operations well into 2025.

What was Know Labs' (KNW) earnings per share for Q3 FY 2024?

Know Labs reported earnings per share of a loss of $0.05 for Q3 FY 2024, an improvement from the prior year loss of $0.07 per share.